Physician profile
Sheila M Gendich
NPI 1124018536
$10,192.61
in general payments reported to CMS, 2019-2025
38 companies · $2,216 in 2025
The $2,216 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,601 · 2020: $1,127 · 2021: $1,020 · 2022: $1,218 · 2023: $1,413 · 2024: $1,597 · 2025: $2,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,111 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,111.17 |
| Education | $115.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,555.70 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,418.01 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $1,394.56 | 2019-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $594.69 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $486.26 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Allergan, INC. | $459.58 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $410.99 | 2019-2025 | Airsupra, Farxiga |
| Indivior INC. | $369.45 | 2019-2025 | Sublocade |
| Alkermes, INC. | $341.20 | 2022-2025 | Aristada, Lybalvi |
| Kowa Pharmaceuticals America, INC. | $328.79 | 2022-2025 | Zoryve, Seglentis, Livalo |
| Mylan Specialty L.P. | $324.18 | 2021-2024 | Yupelri, Yupelri |
| Pfizer INC. | $297.07 | 2019-2025 | |
| Lundbeck LLC | $205.81 | 2020-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $181.78 | 2019-2024 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $177.58 | 2019-2025 | Trintellix, Gattex |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $175.61 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $175.42 | 2023-2025 | Auvelity, Symbravo, Sunosi |
| Orexo US, INC. | $156.62 | 2019-2025 | Zubsolv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.35 | 2019-2021 | |
| Astellas Pharma US INC | $133.70 | 2023-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.85 | 2019 | |
| Glaxosmithkline, LLC. | $109.34 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $105.51 | 2022-2025 | Keveyis, Gvoke Hypopen |
| Braeburn INC. | $98.31 | 2023-2025 | Brixadi |
| Lilly USA, LLC | $50.86 | 2019-2025 | Zepbound, Mounjaro |
| Eisai INC. | $50.19 | 2021-2024 | |
| Exact Sciences Corporation | $48.87 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $44.68 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $44.16 | 2024-2025 | Fanapt, Hetlioz |
| Ibsa Pharma INC. | $35.00 | 2025 | Flector, Licart, Tirosint |
| Uswm, LLC | $28.92 | 2023 | Lucemyra |
| Amgen INC. | $27.25 | 2021-2023 | Repatha, Otezla |
| Sumitomo Pharma America, INC. | $20.21 | 2025 | Gemtesa |
| Tonix Medicines, INC. | $19.75 | 2025 | Tonmya |
| Vertical Pharmaceuticals, LLC | $16.91 | 2019 | |
| Viatris Specialty LLC | $14.54 | 2025 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $12.08 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Gendich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.